In vitro and in vivo responses to short-term recombinant human insulin-like growth factor-1 (IGF-1) in a severely growth-retarded girl with ring chromosome 15 and deletion of a single allele for the type 1 IGF receptor gene

被引:33
作者
de Lacerda, L
Carvalho, JAR
Stannard, B
Werner, H
Boguszewski, MCS
Sandrini, R
Malozowski, SN
LeRoith, D
Underwood, LE
机构
[1] Univ Fed Parana, Dept Paediat, BR-80060000 Curitiba, Parana, Brazil
[2] NIDDK, Diabet Branch, NIH, Bethesda, MD USA
[3] US FDA, Rockville, MD 20857 USA
[4] Univ N Carolina, Dept Paediat, Chapel Hill, NC 27515 USA
关键词
D O I
10.1046/j.1365-2265.1999.00799.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES Patients with single allele defects in the gene encoding the type 1 IGF receptor have been reported to have growth failure, but fibroblasts from affected patients have not exhibited insensitivity to the effects of IGF-I in vitro. The in vitro and in vivo responses to short-term recombinant human IGF-I (rhIGF-I) in a severely growth-retarded girl with ring chromosome 15 and deletion of a single allele for the type 1 IGF receptor gene have been investigated. DESIGN AND PATIENT The child exhibited prenatal and severe post-natal growth failure, and delayed psychomotor development. Southern blotting revealed a 50% reduction in IGF-I receptor DNA, and in an RNase protection assay (RPA), a quantitatively similar reduction in steady-state mRNA for type 1 IGF receptor. rhIGF-I was administered in graded doses of 40, 60 and 80 mu g/kg twice daily by subcutaneous injection for periods of 2-2.5 days each. RESULTS During rhIGF-I treatment, mean urinary nitrogen excretion was unchanged and urinary calcium rose to 60% greater than in the pre-treatment period, rhIGF-I injections produced only a modest decrease in indices of GH secretion, assessed by frequent (every 20 min) sampling over periods of 12 h. There was no significant difference between the mean GH concentrations during rhIGF-I treatment (5.32+/-6.2mU/I) compared with that before rhIGF-I treatment (8.46+/-10.2 mU/I). Mean IGFBP-3-values were increased (4.5 mg/l before vs. 5.4 mg/l during rhIGF-I). TSH values after injection of TRH were not significantly reduced by IGF-I (mean of all values, 18.6 mU/I vs. 15.5 mU/I during rhIGF-I treatment). In vitro binding of radiolabelled IGF-I to the patient's fibroblasts was less than that bound by control fibroblasts (patient, 0.69% binding by 248000 cells, vs. 1 41% binding by 260000 fibroblasts from an age-matched control). However, the patient's fibroblasts exhibited a growth response in vitro to the addition of IGF-I in a fashion similar to that of control fibroblasts. CONCLUSIONS These studies show evidence in each of the indices examined of in vivo resistance to IGF-I and suggest that the growth retardation observed in such patients may be the direct result of the absence of one of the alleles encoding the type 1 IGF receptor.
引用
收藏
页码:541 / 550
页数:10
相关论文
共 40 条
[1]  
ALBERTSSONWIKLA.K, 1989, AM J PHYSL, V257
[2]  
BABA T, 1992, ACTA PAEDIATR SCAND, V383, P111
[3]   Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - A clinical research center study [J].
Backeljauw, PF ;
Underwood, LE ;
Miras, M ;
Arriazu, MC ;
Heinrich, J ;
Ghizzoni, L ;
Blethen, S ;
Donaldson, D ;
Cleveland, W ;
Duncan, V .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (09) :3312-3317
[4]  
BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O
[5]   CIRCULATING LEVELS AND MOLECULAR-DISTRIBUTION OF THE ACID-LABILE (ALPHA) SUBUNIT OF THE HIGH-MOLECULAR-WEIGHT INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN COMPLEX [J].
BAXTER, RC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (05) :1347-1353
[6]   IGF1 GENE DISRUPTION RESULTS IN REDUCED BRAIN SIZE, CNS HYPOMYELINATION, AND LOSS OF HIPPOCAMPAL GRANULE AND STRIATAL PARVALBUMIN-CONTAINING NEURONS [J].
BECK, KD ;
POWELLBRAXTON, L ;
WIDMER, HR ;
VALVERDE, J ;
HEFTI, F .
NEURON, 1995, 14 (04) :717-730
[7]   NEGATIVE FEEDBACK-REGULATION OF PULSATILE GROWTH-HORMONE SECRETION BY INSULIN-LIKE GROWTH-FACTOR-I - INVOLVEMENT OF HYPOTHALAMIC SOMATOSTATIN [J].
BERMANN, M ;
JAFFE, CA ;
TSAI, W ;
DEMOTTFRIBERG, R ;
BARKAN, AL .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (01) :138-145
[8]   BRIEF CLINICAL REPORT AND REVIEW - 2 PATIENTS WITH RING CHROMOSOME-15 SYNDROME [J].
BUTLER, MG ;
FOGO, AB ;
FUCHS, DA ;
COLLINS, FS ;
DEV, VG ;
PHILLIPS, JA .
AMERICAN JOURNAL OF MEDICAL GENETICS, 1988, 29 (01) :149-154
[9]  
CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949
[10]   VARIABLES CONTROLLING THE SECRETION OF INSULIN-LIKE GROWTH-FACTOR BINDING PROTEIN-2 IN NORMAL HUMAN-SUBJECTS [J].
CLEMMONS, DR ;
SNYDER, DK ;
BUSBY, WH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (04) :727-733